<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00464685</url>
  </required_header>
  <id_info>
    <org_study_id>206207-012</org_study_id>
    <nct_id>NCT00464685</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic Macular Edema</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of the intravitreal implant of dexamethasone
      with laser treatment vs. laser treatment alone in patients with diabetic macular edema.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients With at Least 10 Letters of Improvement in Best Corrected Visual Acuity (BCVA) From Baseline in the Study Eye</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>BCVA is measured in the study eye using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates improvement and a decrease in the number of letters read correctly indicates a worsening.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in BCVA in the Study Eye</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>BCVA is measured in the study eye using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates improvement and a decrease in the number of letters read correctly indicates a worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Central Subfield Retinal Thickness in the Study Eye</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Central subfield retinal thickness is assessed in the study eye by Optical Coherence Tomography (OCT). The central subfield is an area in the retina (back of the eye). OCT is a laser-based, noninvasive, diagnostic system that provides high-resolution, three-dimensional images of the retina from which retinal thickness can be measured. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Focal Leakage Area in the Study Eye</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Focal leakage area in the study eye is assessed using fluorescein angiography. A positive number change from baseline indicates a worsening and a negative number change from baseline indicates an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Retreatment in the Study Eye</measure>
    <time_frame>12 Months</time_frame>
    <description>Time to retreatment in the study eye is defined as the number of days between the initial treatment and re-treatment with the study medication.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">253</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>700 µg Dexamethasone Implant and Laser Photocoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Implant and Laser Photocoagulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Initial sham injection with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria.</description>
    <arm_group_label>700 µg Dexamethasone Implant and Laser Photocoagulation</arm_group_label>
    <other_name>Posurdex®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sham injection</intervention_name>
    <description>Initial sham injection with up to 1 additional treatment based on re-treatment criteria.</description>
    <arm_group_label>Sham Implant and Laser Photocoagulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laser Photocoagulation</intervention_name>
    <description>Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.</description>
    <arm_group_label>700 µg Dexamethasone Implant and Laser Photocoagulation</arm_group_label>
    <arm_group_label>Sham Implant and Laser Photocoagulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older with diabetic macular edema

          -  Decrease in visual acuity in at least one eye as a result of macular edema (20/50 or
             worse)

          -  Visual acuity in other eye no worse than 20/200

        Exclusion Criteria:

          -  Known anticipated need for ocular surgery within next 12 months

          -  History of glaucoma or current high eye pressure requiring more than 1 medication

          -  Uncontrolled systemic disease

          -  Known steroid-responder

          -  Use of systemic steroids - Use of Warfarin/Heparin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Artesia</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2007</study_first_submitted>
  <study_first_submitted_qc>April 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2007</study_first_posted>
  <results_first_submitted>July 10, 2014</results_first_submitted>
  <results_first_submitted_qc>July 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 4, 2014</results_first_posted>
  <disposition_first_submitted>January 10, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>January 10, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 20, 2011</disposition_first_posted>
  <last_update_submitted>July 10, 2014</last_update_submitted>
  <last_update_submitted_qc>July 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>700 µg Dexamethasone Implant and Laser Photocoagulation</title>
          <description>Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.</description>
        </group>
        <group group_id="P2">
          <title>Sham Implant and Laser Photocoagulation</title>
          <description>Initial sham injection with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
                <participants group_id="P2" count="127"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>700 µg Dexamethasone Implant and Laser Photocoagulation</title>
          <description>Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.</description>
        </group>
        <group group_id="B2">
          <title>Sham Implant and Laser Photocoagulation</title>
          <description>Initial sham injection with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="126"/>
            <count group_id="B2" value="127"/>
            <count group_id="B3" value="253"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;45 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 to 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With at Least 10 Letters of Improvement in Best Corrected Visual Acuity (BCVA) From Baseline in the Study Eye</title>
        <description>BCVA is measured in the study eye using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates improvement and a decrease in the number of letters read correctly indicates a worsening.</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>Intent to Treat: all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>700 µg Dexamethasone Implant and Laser Photocoagulation</title>
            <description>Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.</description>
          </group>
          <group group_id="O2">
            <title>Sham Implant and Laser Photocoagulation</title>
            <description>Initial sham injection with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With at Least 10 Letters of Improvement in Best Corrected Visual Acuity (BCVA) From Baseline in the Study Eye</title>
          <description>BCVA is measured in the study eye using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates improvement and a decrease in the number of letters read correctly indicates a worsening.</description>
          <population>Intent to Treat: all randomized patients</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8"/>
                    <measurement group_id="O2" value="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in BCVA in the Study Eye</title>
        <description>BCVA is measured in the study eye using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates improvement and a decrease in the number of letters read correctly indicates a worsening.</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>Intent to Treat: all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>700 µg Dexamethasone Implant and Laser Photocoagulation</title>
            <description>Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.</description>
          </group>
          <group group_id="O2">
            <title>Sham Implant and Laser Photocoagulation</title>
            <description>Initial sham injection with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in BCVA in the Study Eye</title>
          <description>BCVA is measured in the study eye using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates improvement and a decrease in the number of letters read correctly indicates a worsening.</description>
          <population>Intent to Treat: all randomized patients</population>
          <units>Letters Read Correctly</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.6" spread="9.38"/>
                    <measurement group_id="O2" value="57.8" spread="9.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="11.45"/>
                    <measurement group_id="O2" value="2.1" spread="12.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Central Subfield Retinal Thickness in the Study Eye</title>
        <description>Central subfield retinal thickness is assessed in the study eye by Optical Coherence Tomography (OCT). The central subfield is an area in the retina (back of the eye). OCT is a laser-based, noninvasive, diagnostic system that provides high-resolution, three-dimensional images of the retina from which retinal thickness can be measured. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>Intent to Treat: all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>700 µg Dexamethasone Implant and Laser Photocoagulation</title>
            <description>Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.</description>
          </group>
          <group group_id="O2">
            <title>Sham Implant and Laser Photocoagulation</title>
            <description>Initial sham injection with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Central Subfield Retinal Thickness in the Study Eye</title>
          <description>Central subfield retinal thickness is assessed in the study eye by Optical Coherence Tomography (OCT). The central subfield is an area in the retina (back of the eye). OCT is a laser-based, noninvasive, diagnostic system that provides high-resolution, three-dimensional images of the retina from which retinal thickness can be measured. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.</description>
          <population>Intent to Treat: all randomized patients</population>
          <units>Microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="438.4" spread="133.93"/>
                    <measurement group_id="O2" value="430.3" spread="131.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-102.8" spread="130.86"/>
                    <measurement group_id="O2" value="-125.3" spread="123.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Focal Leakage Area in the Study Eye</title>
        <description>Focal leakage area in the study eye is assessed using fluorescein angiography. A positive number change from baseline indicates a worsening and a negative number change from baseline indicates an improvement.</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>Intent to Treat: all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>700 µg Dexamethasone Implant and Laser Photocoagulation</title>
            <description>Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.</description>
          </group>
          <group group_id="O2">
            <title>Sham Implant and Laser Photocoagulation</title>
            <description>Initial sham injection with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Focal Leakage Area in the Study Eye</title>
          <description>Focal leakage area in the study eye is assessed using fluorescein angiography. A positive number change from baseline indicates a worsening and a negative number change from baseline indicates an improvement.</description>
          <population>Intent to Treat: all randomized patients</population>
          <units>Millimeters Squared (mm^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.46"/>
                    <measurement group_id="O2" value="1.1" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.96"/>
                    <measurement group_id="O2" value="-0.7" spread="3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Retreatment in the Study Eye</title>
        <description>Time to retreatment in the study eye is defined as the number of days between the initial treatment and re-treatment with the study medication.</description>
        <time_frame>12 Months</time_frame>
        <population>Intent to Treat: all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>700 µg Dexamethasone Implant and Laser Photocoagulation</title>
            <description>Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.</description>
          </group>
          <group group_id="O2">
            <title>Sham Implant and Laser Photocoagulation</title>
            <description>Initial sham injection with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Retreatment in the Study Eye</title>
          <description>Time to retreatment in the study eye is defined as the number of days between the initial treatment and re-treatment with the study medication.</description>
          <population>Intent to Treat: all randomized patients</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189" lower_limit="189" upper_limit="197"/>
                    <measurement group_id="O2" value="196" lower_limit="189" upper_limit="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The Safety Population was used to assess all serious adverse events (SAEs) and adverse events (AEs) and included all patients who were randomized and treated.</desc>
      <group_list>
        <group group_id="E1">
          <title>700 µg Dexamethasone Implant and Laser Photocoagulation</title>
          <description>Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.</description>
        </group>
        <group group_id="E2">
          <title>Sham Implant and Laser Photocoagulation</title>
          <description>Initial sham injection with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory Arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vitreous Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia, Obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Diabetic Foot Infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Staphylococcal Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Incision Site Infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Dialysis Disequilibrium Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Joint Dislocation</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Skull Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemic Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Failure to Thrive</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathic Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Cervical Spinal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Hepatic Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Benign Neoplasm of Thyroid Gland</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer’s Type</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Bladder Neck Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoaesthesia Facial</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="125" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Vitreous Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Visual Acuity Reduced</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Eye Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Vitreous Floaters</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Macular Oedema</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Maculopathy</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Vitreous Detachment</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Retinal Exudates</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Diabetic Retinal Oedema</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Retinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular Pressure Increased</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head,</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

